
Accurate assessment of treatment response to neoadjuvant chemotherapy (NAC) in breast cancer (BC) is crucial for guiding surgical planning. While size-based criteria remain standard, they may underestimate therapy-induced biological changes. To develop and validate the neoadjuvant breast imaging reporting and data system (NacBI-RADS), a structured multiparametric MRI (mp-MRI) lexicon was designed to evaluate NAC response and support surgical decision-making. This retrospective study included 68 BC patients who underwent staging and post-NAC MRI, followed by surgery. mp-MRI examinations included contrast-enhanced T1, T2-weighted, and diffusion-weighted imaging. NacBI-RADS integrates four parameters: peritumoral edema, ΔADC (apparent diffusion coefficient change), post-contrast tumor size, and lymph node status (Node-RADS). Three independent breast radiologists evaluated all cases. Inter-reader agreement was assessed with Cohen’s and Fleiss’ kappa. Of 88 patients assessed, 68 were included. Residual disease was found in 43 patients (63
Chemotherapy-associated steatohepatitis (CASH) increases the risk of postoperative liver failure and mortality in patients undergoing liver surgery. However, non-invasive diagnosis remains an unmet need. Radiomics has potential for characterizing liver parenchyma. This study evaluated the performance of a virtual liver biopsy for CASH prediction, comparing it with whole-liver radiomic analysis. Two retrospective series of patients undergoing hepatectomy for colorectal liver metastases were analyzed: the public “Colorectal-Liver-Metastases” dataset (training and internal validation) and a monocenter series from Humanitas Research Hospital (external validation). Inclusion criteria were preoperative chemotherapy (≥ 2 months) and post-chemotherapy CT (thickness ≤ 5 mm). IBSI-compliant radiomic features were extracted from whole-liver parenchyma and from a virtual biopsy (manually segmented 2-mL cylinder of non-tumoral liver parenchyma). Estimated liver volume (eLV) was computed using three orthogonal diameters. Four XGBoost models were developed (70/30 split, 5-fold cross-validation): clinical; clinical + VB-radiomics (ViB); clinical + VB-radiomics + eLV (ViBE+); clinical + whole-liver radiomics (WholeLiver). One hundred eighty patients were included: 105 internal (63 males, mean age 58.9 years, 38